Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Currently amended) A compound of formula (I):

$$(R)p$$

$$(C)n$$

$$(R^1)q$$

$$(R^1)q$$

$$(I)$$

wherein:

n is 0, 1, or 2;

t is 0 or 1:

X is -NH-, -O-, $-R^{10}$ -, $-R^{10}O$ -, $-R^{10}OR^{10}$ -, $-NR^{10}$ -, $-R^{10}NR^{10}$ -, $-R^{10}NR^{10}$ -, $-R^{10}S(O)_m R^{10}$ -;

Y is -C(O)- or $-S(O)_m$ -;

each R is the same or different and is independently selected from the group consisting of

halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, $-R^{10}$ cycloalkyl, Ay, $-NHR^{10}$ Ay, Het, $-NHR^{10}$ Het, $-OR^2$, -OAy, -OHet, $-R^{10}OR^2$, $-NR^2R^3$, $-NR^2Ay$, $-R^{10}NR^2R^3$, $-R^{10}NR^2Ay$, $-R^{10}C(O)R^2$, $-C(O)R^2$, $-CO_2R^2$, $-R^{10}CO_2R^2$, $-C(O)NR^2R^3$, -C(O)Ay, $-C(O)NR^2Ay$, -C(O)Het, $-C(O)NHR^{10}Het$, $-R^{10}C(O)NR^2R^3$, $-C(S)NR^2R^3$, $-R^{10}C(S)NR^2R^3$, $-R^{10}NHC(NH)NR^2R^3$, $-C(NH)NR^2R^3$, $-R^{10}C(NH)NR^2R^3$, $-R^{10}C(NH)N$

each R¹ is the same or different and is independently selected from the group consisting of halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R¹⁰cycloalkyl, Ay, -NHR¹⁰Ay, Het, -NHHet, -NHR¹⁰Het, -OR², -OAy, -OHet,

 $-R^{10}OR^2$, $-NR^2R^3$, $-NR^2Ay$, $-R^{10}NR^2R^3$, $-R^{10}NR^2Ay$, $-R^{10}C(O)R^2$, $-C(O)R^2$, $-CO_2R^2$,

-R¹⁰CO₂R², -C(O)NR²R³, -C(O)Ay, -C(O)NR²Ay, -C(O)Het, -C(O)NHR¹⁰Het,

 $-R^{10}C(O)NR^2R^3$, $-C(S)NR^2R^3$, $-R^{10}C(S)NR^2R^3$, $-R^{10}NHC(NH)NR^2R^3$,

 $-C(NH)NR^2R^3$, $-R^{10}C(NH)NR^2R^3$, $-S(O)_2NR^2R^3$, $-S(O)_2NR^2Ay$, $-R^{10}SO_2NHCOR^2$,

 $-R^{10}SO_2NR^2R^3, -R^{10}SO_2R^2, -S(O)_mR^2, -S(O)_mAy, \ cyano, \ nitro, \ or \ azido;$

each m independently is 0, 1, or 2;

each R¹⁰ is the same or different and is independently selected from alkylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene;

p and q are each independently selected from 0, 1, 2, 3, 4, or 5;

each of R² and R³ are the same or different and are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R¹⁰cycloalkyl, -R¹⁰OH, -R¹⁰(OR¹⁰)_w, and -R¹⁰NR⁴R⁵;

w is 1-10;

each of R⁴ and R⁵ are the same or different and are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl;

Ay represents an aryl group;

Het represents a 5- or 6-membered heterocyclyl or heteroaryl group;

ring A is aryl or heteroaryl;

provided that when the A ring is aryl, t is 0, and Y is SO₂, then p is not 0; and or a pharmaceutically acceptable salts, or solvates and physiologically functional derivatives thereof.

- 2. (Original) The compound of claim 1 wherein alkyl is C_1 - C_6 alkyl, alkoxy is C_1 - C_6 alkoxy, haloalkyl is C_1 - C_6 haloalkyl, alkylene is C_1 - C_6 alkylene, and alkenylene is C_1 - C_6 alkenylene.
- 3. (Original) The compound wherein t is 0 and Y is -C(O)-.
- 4. (Original) The compound wherein t is 0 and Y is $-S(O)_{m}$.
- 5. (Previously presented) The compound of claim 1 wherein t is 1, Y is -C(O)-, and X is -NH-, -O-, or -R¹⁰.
- 6. (Previously presented) The compound of claim 1 wherein t is 1, Y is $-S(O)_{m^-}$, and X is -NH-, -O-, or $-R^{10}$.

Attorney Docket No. PR60253USW Application No. 10/560,016

- 7. (Original) The compound of claim 1 wherein n is 1.
- 8. (Original) The compound of claim 1 wherein p is 1 or more and R is selected from halogen, alkyl, haloalkyl, -OR², -NR²R³, -C(O)R², -CO₂R², cyano, nitro, or azido.
- 9. (Original) The compound of claim 8 wherein R is halogen, alkyl, haloalkyl.
- (Original) The compound of claim 9 wherein R is substituted para to the depicted N atom.
- 11. (Original) The compound of claim 10 wherein R is halogen.
- 12. (Original) The compound of claim 11 wherein R is Br or Cl.
- 13. (Original) The compound of claim 1 wherein q is 1 or more and R¹ is selected from halogen, alkyl, haloalkyl, -OR², -NR²R³, -C(O)R², -CO₂R², Ay, Het, cyano, nitro, or azido.
- 14. (Original) The compound of claim 13 wherein R¹ is selected from halogen, alkyl, haloalkyl, -OR², -NR²R³, -C(O)R², -CO₂R², or cyano.
- 15. (Original) The compound of claim 14 wherein R² and R³ each are C₁-C₆ alkyl.
- 16. (Original) The compound of claim 14 wherein R¹ is selected from halogen, alkyl, or -OR².
- 17. (Original) The compound of claim 16 wherein said halogen is fluoro or chloro, said alkyl is methyl, and said –OR² is alkoxy.
- 18. (Original) The compound of claim 1 wherein the A ring is aryl.
- 19. (Original) The compound of claim 18 wherein the A ring is phenyl.
- 20. (Original) The compound of claim 19 wherein q is 1 or more and R¹ is selected from halogen, alkyl, haloalkyl, -OR², -NR²R³, -C(O)R², -CO₂R², Ay, Het, cyano, nitro, or azido.
- 21. (Original) The compound of claim 20 wherein q is 1 or more and R¹ is selected from halogen, alkyl, haloalkyl, -OR², -NR²R³, -C(O)R², -CO₂R², or cyano.
- 22. (Original) The compound of claim 1 wherein the A ring is heteroaryl.
- 23. (Original) The compound of claim 22 wherein the heteroaryl is pyridyl.
- 24. (Original) The compound of claim 23 wherein q is 0 or 1.

Attorney Docket No. PR60253USW Application No. 10/560,016

- The compound of claim 24 wherein when q is 1, then 25. (Currently amended) R¹ is is-selected from halogen, alkyl, haloalkyl, -OR², -NR²R³, -C(O)R², -CO₂R², Ay, Het, cyano, nitro, or azido.
- The compound of claim 25 wherein when q is 1, then R¹ is selected 26. (Original) from halogen, alkyl, haloalkyl, -OR², -NR²R³, -C(O)R², -CO₂R², or cyano.
- The compound of claim 1 wherein p is 1, R is halogen, n is 1, Y is -27. (Original) C(O)-, t is 0, ring A is heteroaryl, and q is 0.
- The compound of claim 27 wherein R is chloro and ring A is pyridyl. 28. (Original)
- 29. A compound selected from: (Original)

Attorney Docket No. PR60253USW Application No. 10/560,016

```
30.
      (Original)
                   The compound of claim 1 selected from
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-phenylurea;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N-(4-methoxyphenyl)urea;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-(4-methoxy-2-methylphenyl)urea;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-(3-chloro-4-methoxyphenyl)urea;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N-[4-(dimethylamino)phenyl]urea;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-vl)benzamide:
N-[(1R)-6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl]benzamide;
N-[(1S)-6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl]benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-phenylacetamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-phenylpropanamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-phenylprop-2-enamide;
Benzyl 6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-ylcarbamate;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2,6-dichlorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-nitrobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-chlorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-methylbenzamide:
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-(trifluoromethyl)benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-methylbenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-vl)-2-fluorobenzamide:
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-nitrobenzamide:
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-chlorobenzamide:
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-methylbenzamide;
N-(2,3,4,9-Tetrahydro-1H-carbazol-1-yl)benzamide:
N-(6-Methyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)benzamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)benzamide;
```

```
N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]benzamide;
```

N-[(1S)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;

N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-methylbenzenesulfonamide;

N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)pyridine-2-carboxamide;

N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)nicotinamide;

N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-6-chloronicotinamide;

N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)isonicotinamide;

N-Phenyl-N-(2,3,4,9-tetrahydro-1H-carbazol-1-yl)urea;

N-(6-Methyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-phenylurea;

N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-phenylurea;

N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-pyridinecarboxamide;

N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]pyridine-2-carboxamide;

N-[(1*S*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]pyridine-2-carboxamide;

N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;

N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]-2-fluorobenzamide;

N-[(1S)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]-2-fluorobenzamide;

N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1-methyl-1*H*-imidazole-5-carboxamide;

N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-1-methyl-1H-pyrazole-5-carboxamide;

N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-1-methyl-1H-pyrazole-3-carboxamide:

N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-1H-imidazole-4-carboxamide;

N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-1H-pyrazole-3-carboxamide;

N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2,6-difluorobenzamide;

N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-fluorobenzenesulfonamide; and

N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2,6-difluorobenzenesulfonamide.

```
31.
      (Original)
                   The compound of claim 1 selected from
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-N'-[4-(dimethylamino)phenyl]urea;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)benzamide;
N-[(1R)-6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl]benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-phenylprop-2-enamide;
Benzyl 6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-ylcarbamate;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-nitrobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-chlorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-methylbenzamide:
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-(trifluoromethyl)benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-methylbenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-methylbenzamide;
N-(6-Methyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)benzamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)benzamide;
N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-y]benzamide:
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-methylbenzenesulfonamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)pyridine-2-carboxamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)nicotinamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-6-chloronicotinamide:
N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)isonicotinamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-pyridinecarboxamide:
N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]pyridine-2-carboxamide:
N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2-fluorobenzamide:
N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]-2-fluorobenzamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-1H-imidazole-4-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-1H-pyrazole-3-carboxamide;
```

Attorney Docket No. PR60253USW

Application No. 10/560,016

N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzamide; N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzenesulfonamide; and N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzenesulfonamide.

32. The compound of claim 1 selected from (Original) N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)benzamide; N-[(1R)-6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl]benzamide; Benzyl 6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-ylcarbamate; N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-fluorobenzamide; N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methoxybenzamide; N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-nitrobenzamide: N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-4-chlorobenzamide; N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzamide; N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-fluorobenzamide; N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-3-methoxybenzamide; *N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methylbenzamide; N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide; *N*-(6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide; N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]benzamide;*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzenesulfonamide; N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)pyridine-2-carboxamide; N-(6-Bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-6-chloronicotinamide; N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-pyridinecarboxamide; N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]pyridine-2-carboxamide;N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide; N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]-2-fluorobenzamide; N-(6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-2,6-difluorobenzamide; and N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzenesulfonamide.

33. (Currently amended) The A compound of formula (I) according to claim 1 further comprising:

$$(R)p$$

$$(C)n$$

$$(R^{1})q$$

$$(I)$$

$$(I)$$

including salts, solvates and pharmaceutically functional derivatives, wherein R^6 is H, alkyl, $-OR^2$, $-NR^2R^3$, Ay, Het, $-C(O)R^2$, $-CO_2R^2$, $-CONR^2R^3$, $-S(O)_mR^2$, or oxo, where R^2 , R^3 , m, Ay, and Het are as defined; and R^7 is H or alkyl; provided R^6 and R^7 are not both H, or a pharmaceutically acceptable salt or solvate thereof.

- 34. (Cancelled).
- 35. (Previously presented) A pharmaceutical composition comprising a compound according to claims 1 to 33, and a pharmaceutically acceptable carrier.
- 36 44 (Cancelled).
- 45. (Currently amended) A method for the treatment or prophylaxis of oncogenic viruses, including adenoviruses, retroviruses, and of a papovavirus infection family, including polyoma viruses infection and papilloma viruses infection comprising the administration administering to a subject in need thereof of a therapeutically effective amount of a compound according to any one of claims claim 1 to 33.
- 46. (Currently amended) A method for the treatment or prophylaxis of conditions or disorders due to HPV infection comprising the administration of administering to a subject in need thereof of a therapeutically effective amount of a compound according to any one of claims claim 1 to 33.
- 47. (Original) The method of claim 46 wherein the condition or disorder is warts, genital warts, cervical dysplasia, recurrent respiratory papillomatosis, or cancers associated with papillomavirus infection.